News

The multi-center, open-label Phase 2 Study 010 is designed to assess the safety and pharmacokinetic (PK) effects of four increasing oral doses of AT2220 co-administered with ERT versus

In an independently conducted study, chronic administration of DM-204 prevented disease progression within an in vivo Type 2 diabetes model. Reduction in HbA1c is the critical endpoint measurement

Emergent has humanized anti-CD37 mono-specific protein therapeutic, TRU-016, in development for the treatment of B-cell malignancies. The designation provides benefits such as a seven-year period of marketing exclusivity

The syndrome is a condition of the shoulder in which increased capsular collagen thickening and subsequent capsular contraction in the shoulder joint may cause loss of range of

Gattex is a novel, recombinant analog of human glucagon-like peptide 2, which is involved in gastrointestinal regeneration and repair. The NDA is submitted on the basis of 14

The company took the initiative to bring in a new portfolio of packaging solutions following recommendations and input from hospital pharmacy directors from across the US. Cardinal Health

The dietary supplements are sold under brand names including SynBio, SynOPC, BoneCare, SynBio-X, SynOPC-X, VisionCare, CardioCare, SynGevity, SynVita, SynCell, SynPhyto-K, DigestiveCare, JointCare and SynOmega. The US marshals seized

The product comprises blend of taurine, caffeine, guarana extract, cane sugar and lacks artificial flavors and additives, which the company says, gives a yellow appearance and a medicinal

CardioNova will also become an equity investor in AtheroNova. AHRO-001 is indicated to prevent and regress atherosclerotic plaque as well as reduce cholesterol. Maxwell Biotech Venture Fund has